Shanxi Zhendong Pharmaceutical Co.,Ltd (SHE:300158)

SHE:300158 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	466.17	584.59	800.88	720.27	1,222	926.34
Short-Term Investments	-	5.01	-	-	-	8.61
Trading Asset Securities	708.19	989.62	1,448	2,019	4,470	-
Cash & Short-Term Investments	1,174	1,579	2,249	2,740	5,692	934.95
Cash Growth	-43.17%	-29.78%	-17.91%	-51.87%	508.77%	21.88%
Accounts Receivable	883.27	718.07	856.04	809.3	945.55	1,242
Other Receivables	73.52	57.75	44.71	57.44	502.55	97.62
Receivables	956.79	775.81	900.75	866.74	1,448	1,340
Inventory	643.06	775.98	1,195	1,074	937.14	825.08
Prepaid Expenses	-	6.11	4.18	0.91	2.52	5.26
Other Current Assets	83.91	78.49	111.08	201.62	344.11	714.47
Total Current Assets	2,858	3,216	4,460	4,883	8,424	3,819
Property, Plant & Equipment	1,035	1,046	994.9	1,010	1,047	943.39
Long-Term Investments	43.54	38.65	57.02	58.34	58.3	55.87
Goodwill	15.5	15.5	40.24	40.24	40.24	2,335
Other Intangible Assets	283.66	288.85	260.07	258.39	250.37	199.5
Long-Term Accounts Receivable	-	-	-	0.12	1.11	2.51
Long-Term Deferred Tax Assets	25.4	24.97	21.01	18.87	23.83	29.13
Long-Term Deferred Charges	101.48	101.37	200.37	201.06	195.49	182.76
Other Long-Term Assets	271.75	251.29	146.6	80.41	53.21	35.28
Total Assets	4,635	4,983	6,180	6,551	10,093	7,603
Accounts Payable	280.32	328.01	418	504.48	584.92	289.31
Accrued Expenses	22.33	229.55	251.35	289.2	410.52	593.92
Short-Term Debt	15.25	38.11	0.1	20.48	210.77	413.11
Current Portion of Leases	0.57	2.01	1.22	0.31	0.73	1.5
Current Income Taxes Payable	34.69	-	-	9.33	422.7	10.33
Current Unearned Revenue	49.97	51.42	68.42	147.59	86.59	108.15
Other Current Liabilities	541.45	605.94	177.98	237.93	83.86	291.37
Total Current Liabilities	944.58	1,255	917.07	1,209	1,800	1,708
Long-Term Debt	-	0.18	0.18	-	100.14	32.78
Long-Term Leases	0.95	1.09	1.53	1.08	1.08	-
Long-Term Unearned Revenue	36.66	37.65	42.77	42.49	56.38	77.96
Long-Term Deferred Tax Liabilities	0.96	0.98	0.3	-	-	1.09
Other Long-Term Liabilities	27.72	27.54	74.54	74.72	81.3	150.48
Total Liabilities	1,011	1,322	1,036	1,328	2,039	1,970
Common Stock	1,005	1,005	1,027	1,027	1,027	1,027
Additional Paid-In Capital	3,682	3,682	3,762	3,762	3,762	3,762
Retained Earnings	-905.65	-906.81	421.76	465.74	3,291	856.93
Treasury Stock	-40.38	-2.84	-	-	-	-
Comprehensive Income & Other	-79.78	-79.78	-32.71	-1.39	-1.47	-1.89
Total Common Equity	3,661	3,698	5,179	5,254	8,080	5,645
Minority Interest	-37.52	-37.37	-34.75	-30.86	-25.15	-11.69
Shareholders' Equity	3,624	3,660	5,144	5,223	8,054	5,633
Total Liabilities & Equity	4,635	4,983	6,180	6,551	10,093	7,603
Total Debt	16.77	41.39	3.03	21.87	312.72	447.39
Net Cash (Debt)	1,158	1,538	2,246	2,718	5,379	487.56
Net Cash Growth	-43.92%	-31.52%	-17.36%	-49.48%	1003.25%	-15.85%
Net Cash Per Share	1.15	1.50	2.19	2.64	5.24	0.47
Filing Date Shares Outstanding	995.27	1,024	1,027	1,027	1,027	1,027
Total Common Shares Outstanding	995.27	1,024	1,027	1,027	1,027	1,027
Working Capital	1,914	1,961	3,543	3,674	6,623	2,112
Book Value Per Share	3.68	3.61	5.04	5.11	7.86	5.49
Tangible Book Value	3,362	3,393	4,879	4,956	7,789	3,110
Tangible Book Value Per Share	3.38	3.31	4.75	4.82	7.58	3.03
Buildings	-	1,167	1,144	1,094	1,033	911.92
Machinery	-	864.1	832.12	824.63	783.61	700.62
Construction In Progress	-	119.4	44.98	24.21	19.89	9.56

Updated Oct 23, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.